Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011570 (
depression
)
172,036
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Depressive disorder (DD) is characterised by disturbances in blood melatonin concentration. It is well known that melatonin is involved in the control of circadian rhythms, sleep included. The use of melatonin and its analogues has been found to be effective in
depression
therapy. Melatonin synthesis is a multistage process, where the last stage is catalysed by
acetylserotonin methyltransferase
(
ASMT
), the reported rate-limiting melatonin synthesis enzyme. Taking into account the significance of genetic factors in
depression
development, the gene for
ASMT
may become an interesting focus for studies in patients with recurrent DD. The goal of the study was to evaluate two single-nucleotide polymorphisms (SNPs) (rs4446909; rs5989681) of the
ASMT
gene, as well as mRNA expression for
ASMT
in recurrent DD-affected patients. We genotyped two polymorphisms in a group of 181 recurrent DD patients and in 149 control subjects. The study was performed using the polymerase chain reaction/restriction fragment length polymorphism method. The distribution of genotypes in both studied SNPs in the
ASMT
gene differed significantly between DD and healthy subjects. The presence of AA genotype of rs4446909 polymorphism and of GG genotype of rs5989681 polymorphism was associated with lower risk for having recurrent DD. In turn, patients with
depression
were characterised by reduced mRNA expression for
ASMT
. In addition,
ASMT
transcript level in both recurrent DD patients and in healthy subjects depended significantly on genotype distributions in both polymorphisms. In conclusion, our results suggest the
ASMT
gene as a susceptibility gene for recurrent DD.
...
PMID:Single-nucleotide polymorphisms and mRNA expression for melatonin synthesis rate-limiting enzyme in recurrent depressive disorder. 2043 39
Patients affected by bipolar disorder (BD) frequently report abnormalities in sleep/wake cycles. In addition, they showed abnormal oscillating melatonin secretion, a key regulator of circadian rhythms and sleep patterns. The
acetylserotonin O-methyltransferase
(
ASMT
) is a key enzyme of the melatonin biosynthesis and has recently been associated with psychiatric disorders such as autism spectrum disorders and
depression
. In this paper, we analysed rare and common variants of
ASMT
in patients with BD and unaffected control subjects and performed functional analysis of these variants by assaying the
ASMT
activity in their B-lymphoblastoid cell lines. We sequenced the coding and the regulatory regions of the gene in a discovery sample of 345 patients with BD and 220 controls. We performed an association study on this discovery sample using common variants located in the promoter region and showed that rs4446909 was significantly associated with BD (P= 0.01) and associated with a lower mRNA level (P< 10(-4)) and a lower enzymatic activity (P< 0.05) of
ASMT
. A replication study and a meta-analysis using 480 independent patients with BD and 672 controls confirmed the significant association between rs4446909 and BD (P= 0.002). These results correlate with the general lower
ASMT
enzymatic activity observed in patients with BD (P= 0.001) compared with controls. Finally, several deleterious
ASMT
mutations identified in patients were associated with low
ASMT
activity (P= 0.01). In this study, we determined how rare and common variations in
ASMT
might play a role in BD vulnerability and suggest a general role of melatonin as susceptibility factor for BD.
...
PMID:Genetic and functional abnormalities of the melatonin biosynthesis pathway in patients with bipolar disorder. 2269 57